10-Q: Ocugen Faces Going Concern Doubt Amid Rising Losses

Ocugen reported increased net losses and a going concern warning, despite pipeline progress and a new licensing deal, as a merger agreement terminated.

Summary

• Ocugen incurred a net loss of $50.1 million for the nine months ended September 30, 2025, compared to $40.2 million for the same period in 2024.
• The company's cash balance stood at $32.6 million as of September 30, 2025, which is insufficient to fund operations for the next 12 months, leading to a 'going concern' warning.
• Research and development expenses increased to $29.1 million for the nine months ended September 30, 2025, up from $23.8 million in the prior year, driven by clinical activities for OCU400 and OCU410ST.
• General and administrative expenses rose to $21.4 million for the nine months ended September 30, 2025, compared to $20.4 million in 2024, primarily due to professional services fees related to business development.
• A merger agreement for the NeoCart business with Carisma Therapeutics Inc. was terminated on September 16, 2025, due to Ocugen's failure to secure $25.0 million in concurrent investment.
• Ocugen completed a registered direct offering in August 2025, raising $18.5 million in net proceeds from the sale of 20 million shares and accompanying warrants.
• A new exclusive license agreement was signed with Kwangdong Pharmaceutical, Ltd. in September 2025 for the development and commercialization of OCU400 in South Korea, including an initial $0.8 million non-refundable fee.
• The company is actively recruiting for the Phase 3 liMeliGhT clinical trial for OCU400 (retinitis pigmentosa) and initiated dosing in the Phase 2/3 GARDian3 pivotal confirmatory trial for OCU410ST (Stargardt disease).
• Positive two-year data from the OCU400 Phase 1/2 trial showed statistically significant improvement in low luminance visual acuity (LLVA) in all evaluable treated subjects.
• The EMA granted ATMP classification for OCU400, OCU410, and OCU410ST, and accepted a single U.S.-based trial for OCU410ST's Marketing Authorization Application (MAA) submission.
• Ongoing legal proceedings include an appealed securities class action lawsuit and several stockholder derivative lawsuits, with a new securities class action filed in October 2025.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including increased losses, a substantial accumulated deficit, and an explicit 'going concern' warning. While there is notable progress in the clinical pipeline and a new licensing deal, these positives are overshadowed by the immediate liquidity concerns, the termination of a merger agreement, and ongoing legal issues. The need for significant additional capital in the near term creates high uncertainty.

Positives

• Collaborative arrangement revenue increased by $1.3 million to $4.6 million for the nine months ended September 30, 2025, compared to $3.3 million in 2024.
• OCU400 (retinitis pigmentosa) is actively recruiting subjects in the Phase 3 liMeliGhT clinical trial in the United States and Canada, targeting BLA and MAA filings in 2026.
• Positive two-year data from the OCU400 Phase 1/2 clinical trial demonstrated clinically meaningful and statistically significant (p=0.005) improvement in low luminance visual acuity (LLVA) in all evaluable treated subjects.
• The European Commission (EC) provided a positive opinion from the European Medicines Agency's (EMA) Committee for Advanced Therapies for OCU400 Advanced Therapy Medicinal Product (ATMP) classification, accelerating regulatory review.
• OCU410ST (Stargardt disease) initiated dosing in the Phase 2/3 GARDian3 pivotal confirmatory trial in July 2025, representing the company's second late-stage clinical program with a target BLA submission in 2027.
• The FDA granted Rare Pediatric Disease Designation (RPDD) for OCU410ST, and the EMA granted orphan medicinal product designation (OMPD), supporting its development for ABCA4-associated retinopathies.
• The EMA's Committee for Medicinal Products for Human Use (CHMP) accepted a single U.S.-based trial for OCU410ST's Marketing Authorization Application (MAA) submission, potentially streamlining European approval.
• OCU410 (geographic atrophy) completed dosing in Phase 2 of the Phase 1/2 ArMaDa trial, showing positive preliminary efficacy and safety data including reduced lesion growth and preservation of retinal tissue.
• Preliminary results from the OCU410 Phase 2 clinical trial demonstrated 27% slower geographic atrophy (GA) lesion growth at 6 months, which is greater than published data from approved products like Pegcetacoplan Monthly (13% reduction at 6 months and up to 22% at 24 months) and Pegcetacoplan Every Other Month (12% reduction at 6 months and 18% at 24 months).
• OCU200 (diabetic macular edema, diabetic retinopathy, wet age-related macular degeneration) dosed its first subject in a Phase 1 clinical trial in January 2025 and is on track to complete enrollment in Q1 2026.
• The Investigational New Drug (IND) application for OCU500 (COVID-19 vaccine) is in effect, with the National Institute of Allergy and Infectious Diseases (NIAID) intending to initiate a Phase 1 clinical trial.
• A new exclusive license agreement with Kwangdong Pharmaceutical, Ltd. for OCU400 in South Korea includes an initial $0.8 million non-refundable fee and potential milestone payments, addressing an estimated 7,000 RP patients in the region.

Negatives

• Net loss increased to $50.1 million for the nine months ended September 30, 2025, from $40.2 million in the prior year.
• Cash and restricted cash decreased significantly to $32.9 million as of September 30, 2025, from $58.8 million at the beginning of the period.
• The company has an accumulated deficit of $390.4 million as of September 30, 2025.
• Net cash used in operating activities increased to $43.0 million for the nine months ended September 30, 2025, from $31.8 million in the prior year, indicating higher cash burn.
• Interest expense for the nine months ended September 30, 2025, increased significantly to $3.8 million, compared to $0.1 million for the same period in 2024, due to long-term debt.
• The merger agreement for the NeoCart business with Carisma Therapeutics Inc. was terminated on September 16, 2025, due to Ocugen's failure to secure $25.0 million in concurrent investment.
• A one-time contract termination fee of $1.3 million was recorded in the three months ended September 30, 2025, contributing to other expense.
• The timing of the NIAID-sponsored Phase 1 clinical trial for OCU500 is unknown due to the current U.S. government shutdown.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern within one year due to recurring net losses and insufficient cash to fund operations.
• The company will require significant additional funding to continue research, development, and commercialization efforts, which may not be available on favorable terms or at all.
• Failure to obtain necessary funding could lead to delays, scaling back, or elimination of research and development programs and commercialization efforts, or even cessation of operations.
• The issuance of a substantial number of warrants and equity awards could result in significant dilution to existing stockholders.
• Sales of a large number of common stock shares or exercise and sale of warrants in the public market could depress the stock price.
• Changes in funding or disruptions at the FDA, SEC, NIH, and other government agencies (e.g., government shutdowns) could hinder regulatory approvals, clinical trial initiations, and overall business operations.
• Geopolitical events, including global conflicts, economic sanctions, and trade restrictions (e.g., tariffs), could disrupt business, supply chains, and increase operational costs, especially given operations in China with CanSinoBIO.
• The potential impact of legislative proposals like the BIOSECURE Act, which could restrict federal government contracts/loans for biotechnology providers with relationships with foreign adversaries, poses a risk to operations in China.
• Ongoing legal proceedings, including securities class action and stockholder derivative lawsuits, could result in significant damages, legal costs, and potential governance reforms.

Future Outlook

Ocugen plans to complete enrollment for the OCU200 Phase 1 clinical trial in Q1 2026. The company is on track to complete enrollment for the OCU400 Phase 3 liMeliGhT clinical trial and targets BLA and MAA filings in 2026. For OCU410ST, a BLA submission is planned for 2027. The company continues to explore options to fund operations through public and private placements of equity and/or debt, strategic research and development arrangements, asset sales, licensing/collaboration, and government funding.

Management Comments

• Management believes it has a plan to fund operations, but acknowledges it may not be successfully implemented.
• Management states that if necessary funding cannot be obtained, the company will need to delay, scale back, or eliminate some or all research and development programs and commercialization efforts, or consider strategic alternatives including merger, sale, or cessation of operations.
• Management believes their novel modifier gene therapy platform has the potential to address major blindness diseases with a gene-agnostic approach.
• Management believes OCU410 has the potential to provide a one-time treatment for life for the 2-3 million people in the U.S. & EU combined who suffer from GA.
• Management is continuing discussions with relevant government agencies and strategic partners regarding developmental funding for the OCU510 and OCU520 vaccine platforms.

Industry Context

Ocugen operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on gene therapies for retinal diseases and vaccine platforms. The company's modifier gene therapy approach (OCU400, OCU410ST, OCU410) aims to differentiate itself from single-gene replacement therapies by targeting multiple pathways. The termination of the NeoCart merger highlights the challenges in securing financing for regenerative medicine assets. The reliance on government funding for vaccine platforms (OCU500, OCU510, OCU520) exposes the company to political and budgetary uncertainties, as evidenced by the US government shutdown impacting the OCU500 trial. The licensing deal with Kwangdong Pharmaceutical for OCU400 in South Korea indicates a strategy to expand market reach through partnerships, a common approach in the biopharma industry for regional commercialization.

Comparison to Industry Standards

• OCU410's preliminary Phase 2 data showed 27% slower geographic atrophy (GA) lesion growth at 6 months, which is greater than published data from approved products like Pegcetacoplan Monthly (13% reduction at 6 months and up to 22% at 24 months) and Pegcetacoplan Every Other Month (12% reduction at 6 months and 18% at 24 months). This suggests a potentially superior efficacy profile for OCU410 in GA treatment.
• The EMA's acceptance of a single U.S.-based trial for OCU410ST's Marketing Authorization Application (MAA) submission is a significant positive, potentially streamlining the regulatory pathway in Europe compared to typical requirements for multiple regional trials.

Corporate Governance

Legal Proceedings

• A securities class action lawsuit (Case No. 2:24-cv-01500) filed in April 2024, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5, had its motion to dismiss granted in July 2025. The lead plaintiff appealed to the Third Circuit in October 2025, with the company's brief due in December 2025 and the plaintiff's reply in January 2026.
• Five stockholder derivative lawsuits (consolidated under Case No. 2:24-cv-02234) filed in May 2024, Q3 2024, and January 2025, alleging breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of Section 14(a) and 10(b) of the Exchange Act. These lawsuits are stayed pending the appeal of the related securities class action.
• A new securities class action lawsuit (Case No. 2025-1214) was filed in the Delaware Court in October 2025, alleging breach of contract, declaratory judgment under 8 Del. C. § 225(b) and 10 Del. C. § 6501, based on allegations that the company breached charter provisions and attempted to evade voting thresholds. This lawsuit seeks unspecified damages, interest, attorneys' fees, injunctive relief, and other governance-related actions.

Stakeholder Impact

• Shareholders face significant dilution risk from the issuance of new shares and warrants, as well as potential stock price volatility due to the 'going concern' warning, increased losses, and ongoing legal challenges.
• Employees may face uncertainty regarding job security and future growth opportunities if the company fails to secure additional funding or if R&D programs are delayed or eliminated.
• Patients awaiting therapies for retinal diseases (RP, Stargardt, GA) and vaccines (COVID-19, flu) could experience delays in access to potential treatments if clinical trials are slowed or funding is insufficient.
• Creditors (e.g., Avenue Capital Management II, L.P.) are exposed to increased risk due to the company's 'going concern' status and accumulated deficit, despite collateralized debt.
• Partners like CanSinoBIO and Kwangdong Pharmaceutical may face operational impacts if Ocugen's financial instability affects its ability to fulfill co-development, manufacturing, or support obligations.

Next Steps

• Complete enrollment for the OCU200 Phase 1 clinical trial in Q1 2026.
• Complete enrollment for the OCU400 Phase 3 liMeliGhT clinical trial.
• Target BLA and MAA filings for OCU400 in 2026.
• Continue dosing patients for the OCU410ST Phase 2/3 pivotal confirmatory trial.
• Target BLA submission for OCU410ST in 2027.
• NIAID intends to initiate a Phase 1 clinical trial for OCU500 (timing unknown due to government shutdown).
• Continue discussions with government agencies and strategic partners for developmental funding for OCU510 and OCU520 vaccine platforms.
• Pursue new strategic partnerships and investment opportunities following the NeoCart merger termination.
• File appellees brief in December 2025 for the appeal of the securities class action lawsuit.
• Lead plaintiff's reply brief due in January 2026 for the appeal of the securities class action lawsuit.

Key Dates

Recommendation

The filing presents a dire financial situation with an explicit 'going concern' warning, indicating that current cash reserves are insufficient for the next 12 months. The company reported significantly increased net losses and cash burn, alongside a substantial accumulated deficit. The termination of a merger agreement due to a failure to secure concurrent investment further underscores financing difficulties. While there is clinical pipeline progress and a new licensing deal, these positives are heavily outweighed by the immediate and severe liquidity risks, the high probability of further dilution through future capital raises, and the uncertainty introduced by multiple ongoing legal proceedings. A seasoned investor would view the 'going concern' warning as a critical red flag, suggesting a high risk of significant capital loss and recommending divestment.

Keywords

gene therapy, retinitis pigmentosa, Stargardt disease, geographic atrophy, ocular diseases, biotechnology, clinical trials, OCU400, OCU410ST, OCU410, OCU200, OCU500, vaccine platform, going concern, capital raise, SEC filing, 10-Q, financial results, biopharmaceutical